Ferroptosis/apoptosis inducer-5
Ferroptosis/apoptosis inducer-5 is an orally active inducer of Ferroptosis and Apoptosis. Ferroptosis/apoptosis inducer-5 downregulates GPX4, upregulates ACSL4, promotes ROS production, activates the Caspase cascade, induces Mitochondrial dysfunction, and alters the Bcl-2/Bax balance. Ferroptosis/apoptosis inducer-5 significantly inhibits tumor growth in a pancreatic cancer xenograft mouse model. Ferroptosis/apoptosis inducer-5 can be used for the research of pancreatic cancer.
For research use only. We do not sell to patients.
- CAS No.: 2243423-32-5
- Formula: C53H72BrO3P
- Molecular Weight:868.01
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Caspase Isoforms
More
Biological Activity
|
Bax |
Bcl-2 |
GPX4 |
ACSL4 |
Ferroptosis/apoptosis inducer-5 (Compound 14) (1.36 μM; 48 h) potently and selectively inhibits the viability of PANC-1 pancreatic cancer cells with an IC50 of 1.36 μM, while showing weaker cytotoxicity against normal 3T3-L1 cells[1].
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 48 h treatment, followed by 10 days of culture without compound) dose-dependently inhibits the long-term colony-forming ability of PANC-1 pancreatic cancer cells, with near-complete suppression at 2.0 μM[1].
Ferroptosis/apoptosis inducer-5 (0.125-2.0 μM; 24 h, 48 h) inhibits the proliferation of PANC-1 pancreatic cancer cells in a concentration- and time-dependent manner, with significant effects observed at 0.25-2.0 μM over 48 h[1].
Ferroptosis/apoptosis inducer-5 (0.125-0.5 μM; 24 h) dose-dependently inhibits the migration and invasive potential of PANC-1 pancreatic cancer cells, with significant effects at 0.5 μM over 24 h[1].
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 48 h) dose-dependently induces G0/G1 phase arrest in PANC-1 pancreatic cancer cells, inhibiting cell proliferation by blocking completion of the replication cycle[1].
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 24 h) dose-dependently increases intracellular ROS levels in PANC-1 pancreatic cancer cells, with significant elevation at 0.5 μM over 24 h[1].
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 48 h) dose-dependently induces apoptosis in PANC-1 pancreatic cancer cells, as evidenced by classical apoptotic morphological changes after 48 h of incubation[1].
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 24 h) activates the intrinsic mitochondrial apoptotic pathway in PANC-1 pancreatic cancer cells by altering Bcl-2/Bax balance, promoting cytochrome c release, and activating the caspase cascade after 24 h of incubation[1].
Ferroptosis/apoptosis inducer-5 (0.5-2.0 μM; 24 h) induces ferroptosis in PANC-1 pancreatic cancer cells by downregulating GPX4 and upregulating ACSL4 after 24 h of incubation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human pancreatic cancer PANC-1 cells, human choroidal melanoma C918 cells, mouse embryonic fibroblast 3T3-L1 cells
-
Concentration:1.36 μM (PANC-1 IC50); 9.25 μM (3T3-L1 IC50)
-
Incubation Time:48 h
-
Result:Showed potent cytotoxicity against PANC-1 cells with an IC50 of 1.36 μM, far superior to parent betulinic acid (IC50 = 79.29 μM).
Exhibited selective cytotoxicity with an IC50 of 9.25 μM against normal 3T3-L1 cells.
Displayed strong activity against C918 cells.
-
Cell Line:human pancreatic cancer PANC-1 cells
-
Concentration:0.5-2.0 μM
-
Incubation Time:48 h treatment, followed by 10 days of culture without compound
-
Result:Significantly inhibited PANC-1 colony formation in a concentration-dependent manner.
Almost completely suppressed colony formation at 2.0 μM.
-
Cell Line:human pancreatic cancer PANC-1 cells
-
Concentration:0.125-2.0 μM
-
Incubation Time:24 h, 48 h
-
Result:Inhibited PANC-1 cell proliferation in a concentration- and time-dependent manner.
Showed no significant effect at 0.125-0.5 μM over 24 h.
Produced significant inhibition at 0.25-2.0 μM over 48 h.
-
Cell Line:human pancreatic cancer PANC-1 cells
-
Concentration:0.5-2.0 μM
-
Incubation Time:48 h
-
Result:Induced dose-dependent G1 phase arrest in PANC-1 cells.
Increased G1 phase cell percentage.
Decreased S phase cell percentage.
Caused a slight reduction in G2 phase cell percentage.
-
Cell Line:human pancreatic cancer PANC-1 cells
-
Concentration:0.5-2.0 μM
-
Incubation Time:48 h
-
Result:Induced a dose-dependent increase in apoptotic PANC-1 cells.
Caused enhanced blue fluorescence (nuclear condensation/fragmentation) and increased red fluorescence (cell membrane integrity loss).
-
Cell Line:human pancreatic cancer PANC-1 cells
-
Concentration:0.5-2.0 μM
-
Incubation Time:24 h
-
Result:Dose-dependently upregulated pro-apoptotic Bax and cytosolic cytochrome c.
Downregulated anti-apoptotic Bcl-2.
Increased levels of Cleaved-Caspase-9 and Cleaved-Caspase-3.\nDose-dependently downregulated anti-ferroptotic GPX4.
Upregulated pro-ferroptotic ACSL4.
| Species | Dose | Route | Tmax | Cmax | T1/2 | AUC0-∞ | MRT0-∞ |
|---|---|---|---|---|---|---|---|
| Rat[1] | 20 mg/kg | p.o. | 4.0 h | 49.30 μg/mL | 5.47 h | 337.29 μg·h/mL | 7.53 h |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 6 weeks old, 17-20 g, SPF grade, subcutaneous xenograft model via Panc02 cell injection)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:i.p.; every 2 days; 28 days
-
Result:Reduced tumor weight by 37.1% relative to control.
Reduced tumor weight by 57.0% relative to control.
Reduced tumor weight by 68.9% relative to control, with no significant difference in tumor inhibition rate compared to positive control gemcitabine.
Showed dose-dependent reduction in tumor volume over the 28-day treatment period.
Induced dose-dependent tumor cell apoptosis (increased TUNEL-positive cells), reduced cell proliferation (decreased Ki-67 staining), and downregulated GPX4 expression (indicating ferroptosis induction) in tumor tissues.
Caused no significant pathological abnormalities in heart, liver, spleen, lung, or kidney tissues; serum levels of ALT, AST, BUN, and creatinine were statistically unchanged relative to control.
Chemical Information
-
CAS No. 2243423-32-5
-
Molecular Weight 868.01
-
Formula C53H72BrO3P
-
SMILES
O=C(OCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)[C@@]45CC[C@@]6(C)[C@]7(C)CC[C@@]8([H])C(C)(C)[C@@H](O)CC[C@]8(C)[C@@]7([H])CC[C@]6([H])[C@@]4([H])[C@H](C(C)=C)CC5.[Br-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ferroptosis/apoptosis inducer-5 Related Classifications
HY-183791A Related Classifications
Powered by Bioz
- Ferroptosis/apoptosis inducer-5
- 2243423-32-5
- Ferroptosis
- Apoptosis
- Glutathione Peroxidase
- ACSL Family
- Reactive Oxygen Species (ROS)
- Mitochondrial Metabolism
- Caspase
- Bcl-2 Family
- Bcl-2
- Bax
- apoptosis
- pancreatic cancer xenograft mouse models
- ferroptosis
- GPX4
- PANC-1 pancreatic cancer cells
- ACSL4
- pancreatic cancer
- 3T3-L1 cells
- Inhibitor
- inhibitor
- inhibit